SAN DIEGO and BRISBANE, Calif., Sept. 12, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Hyperion Therapeutics, Inc. breached their fiduciary duties to shareholders. Hyperion is a commercial biopharmaceutical company focused on the development and commercialization of therapeutics to treat disorders affecting the liver, gallbladder, biliary tree, pancreas, as well as orphan diseases.
View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/hyperion-therapeutics-inc
Hyperion Announces Collusion between Andromeda Biotech, Ltd. Employees and Third-Party Biostatistics Firm
On September 8, 2014, Hyperion revealed that it is terminating the development of DiaPep277, used for treating newly diagnosed Type 1 diabetes patients, due to misconduct by recently acquired, Andromeda Biotech, Ltd. employees. Hyperion announced that it had uncovered evidence that indicates certain Andromeda employees colluded with a third party biostatistics firm to share and examine un-blinded data from the DIA-AID 1 and the ongoing DIA-AID 2 trial. Andromeda employees then used this shared data to manipulate the analyses to obtain favorable results in the DIA-AID 1 trial.
Hyperion Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.